In patients with non-metastatic castration-sensitive prostate cancer (nmCSPC), PSA dynamics following ADT initiation, including PSA rebound or sustained elevation, are prognostic for the risk of progression to CRPC and prostate cancer-specific mortality 18, 19. This evidence concerns the gene KLK3 and prostate carcinoma.